Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: EBF2

Gene summary for EBF2

Gene summary.

Gene information	Species	Human
	Gene symbol	EBF2
	Gene ID	64641
	Gene name	EBF transcription factor 2
	Gene Alias	COE2
	Cytomap	8p21.2
	Gene Type	protein-coding
	GO ID	GO:0001659
	UniProtAcc	B2RNT0

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
64641	EBF2	ATC12	Human	Thyroid	ATC	4.23e-28	5.17e-01	0.34
64641	EBF2	ATC13	Human	Thyroid	ATC	1.88e-57	9.99e-01	0.34
64641	EBF2	ATC4	Human	Thyroid	ATC	2.45e-37	6.47e-01	0.34
64641	EBF2	ATC5	Human	Thyroid	ATC	1.85e-55	1.08e+00	0.34

Page: 1

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:005123526	Skin	AK	maintenance of location	56/1910	327/18723	7.44e-05	1.06e-03	56
GO:00072198	Skin	AK	Notch signaling pathway	34/1910	172/18723	1.20e-04	1.50e-03	34
GO:000660526	Skin	AK	protein targeting	53/1910	314/18723	1.67e-04	1.94e-03	53
GO:19028959	Skin	AK	positive regulation of pri-miRNA transcription by RNA polymerase II	13/1910	42/18723	1.85e-04	2.12e-03	13
GO:007058524	Skin	AK	protein localization to mitochondrion	26/1910	125/18723	3.17e-04	3.24e-03	26
GO:003166727	Skin	AK	response to nutrient levels	72/1910	474/18723	3.74e-04	3.63e-03	72
GO:00085936	Skin	AK	regulation of Notch signaling pathway	21/1910	95/18723	4.96e-04	4.58e-03	21
GO:000698417	Skin	AK	ER-nucleus signaling pathway	13/1910	46/18723	5.02e-04	4.61e-03	13
GO:003166924	Skin	AK	cellular response to nutrient levels	38/1910	215/18723	5.37e-04	4.86e-03	38
GO:001082120	Skin	AK	regulation of mitochondrion organization	28/1910	144/18723	6.05e-04	5.32e-03	28
GO:000683926	Skin	AK	mitochondrial transport	43/1910	254/18723	6.18e-04	5.42e-03	43
GO:001050618	Skin	AK	regulation of autophagy	51/1910	317/18723	6.97e-04	5.96e-03	51
GO:190374710	Skin	AK	regulation of establishment of protein localization to mitochondrion	13/1910	50/18723	1.19e-03	9.11e-03	13
GO:000926720	Skin	AK	cellular response to starvation	28/1910	156/18723	2.15e-03	1.43e-02	28
GO:007265524	Skin	AK	establishment of protein localization to mitochondrion	23/1910	120/18723	2.17e-03	1.44e-02	23
GO:190300810	Skin	AK	organelle disassembly	22/1910	114/18723	2.44e-03	1.59e-02	22
GO:004259420	Skin	AK	response to starvation	32/1910	197/18723	5.47e-03	3.02e-02	32
GO:000042218	Skin	AK	autophagy of mitochondrion	16/1910	81/18723	7.13e-03	3.64e-02	16
GO:006172618	Skin	AK	mitochondrion disassembly	16/1910	81/18723	7.13e-03	3.64e-02	16
GO:19037499	Skin	AK	positive regulation of establishment of protein localization to mitochondrion	9/1910	36/18723	8.65e-03	4.28e-02	9

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

TF	Cell Type	Tissue	Disease Stage	Target Gene	RSS	Regulon Activity
EBF2	ECM	Oral cavity	ADJ	PLAC9,EFHD1,MFAP5, etc.	7.18e-01
EBF2	ECM	Oral cavity	OSCC	PLAC9,EFHD1,MFAP5, etc.	1.13e-01

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

EBF2

SNV

Missense_Mutation

c.1373C>T

p.Pro458Leu

p.P458L

Q9HAK2

protein_coding

deleterious_low_confidence(0.04)

possibly_damaging(0.593)

TCGA-A7-A26H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

anastrozole

EBF2

SNV

Missense_Mutation

novel

c.202N>T

p.His68Tyr

p.H68Y

Q9HAK2

protein_coding

deleterious(0)

probably_damaging(0.911)

TCGA-AC-A2QI-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Chemotherapy

cytoxan

EBF2

SNV

Missense_Mutation

c.469N>A

p.Glu157Lys

p.E157K

Q9HAK2

protein_coding

deleterious(0)

possibly_damaging(0.6)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

EBF2

SNV

Missense_Mutation

c.1468N>G

p.Leu490Val

p.L490V

Q9HAK2

protein_coding

deleterious_low_confidence(0.02)

possibly_damaging(0.816)

TCGA-BH-A0AW-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

carboplatin

EBF2

SNV

Missense_Mutation

c.421N>A

p.Glu141Lys

p.E141K

Q9HAK2

protein_coding

deleterious(0.02)

probably_damaging(0.997)

TCGA-BH-A0DP-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

arimidex

EBF2

SNV

Missense_Mutation

novel

c.1204N>G

p.Leu402Val

p.L402V

Q9HAK2

protein_coding

deleterious_low_confidence(0.03)

probably_damaging(0.911)

TCGA-BH-A2L8-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cytoxan

EBF2

SNV

Missense_Mutation

novel

c.599C>G

p.Thr200Arg

p.T200R

Q9HAK2

protein_coding

deleterious(0)

benign(0.142)

TCGA-D8-A1JP-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

tamoxiphen

EBF2

SNV

Missense_Mutation

novel

c.725N>C

p.Arg242Thr

p.R242T

Q9HAK2

protein_coding

deleterious(0)

possibly_damaging(0.491)

TCGA-EW-A423-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

anastrozole

EBF2

SNV

Missense_Mutation

novel

c.8N>A

p.Gly3Glu

p.G3E

Q9HAK2

protein_coding

deleterious_low_confidence(0.04)

benign(0.018)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

EBF2

SNV

Missense_Mutation

c.1138C>G

p.Leu380Val

p.L380V

Q9HAK2

protein_coding

tolerated(0.06)

benign(0.148)

TCGA-VS-A954-01

Cervix

cervical & endocervical cancer

Female

>=65

III/IV

Chemotherapy

cisplatin

Page: 1 2 3 4 5 6 7 8 9

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1